Fennec Pharmaceuticals FENC Insider Ownership

NASDAQ FENC

$10.35 -0.11 (-1.05%)

As of: Oct 21, 2026 · 3:24 PM EDT

Insider Holdings by Owner

3.57Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

10.03%

▼-0.173% pp QoQ

Shares Held by Insiders

3.51Mn

filed for Sep 2026

▼-1.70% QoQ

Shares Outstanding

35.03Mn

35,034,000 shares

Direct Holdings

767.96K

Indirect: 2.74Mn

Net Shares Traded (QoQ)

-60.68K

net selling in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 16, 2026

Over the past year, FENC insiders sold $11.9 million of stock (1.49Mn shares) on the open market and bought none.

By number of insiders, Fennec Pharmaceuticals saw 6 insiders sell on the open market over the past 12 months and none buy.
The largest open-market sales of FENC in the past 12 months were by Southpoint Capital Advisors LP (10% owner), totaling $9.71 million (1.27Mn shares), most recently on December 24, 2025.
Marco Maria Brughera (Director) made the most recent open-market trade by an insider of Fennec Pharmaceuticals, a sale of 15.54K shares for $159,958 on September 15, 2026.
Beyond open-market trades, insiders at Fennec Pharmaceuticals received 79.62K shares in stock awards and acquired 363.21K shares through option exercises and conversions in the last 12 months.
Per Business Quant, FENC insiders together hold 3.53Mn shares based on their latest Form 4 filings, down 1.25% from 3.57Mn shares at the end of Q2 2026.
By type of ownership, FENC insiders hold 22.22% of their shares directly (784.14K shares) and 77.78% indirectly (2.74Mn shares).
The insider holdings in Fennec Pharmaceuticals belong to 9 insiders who have reported on Form 4 within the past two years.
FENC's three largest insider shareholders, per their latest Form 4 filings, are Southpoint Capital Advisors LP (10% owner, 2.74Mn shares), Robert Andrade (Chief Financial Officer, 246.85K shares) and Khalid Islam (Director, 213.82K shares).
The holding of Southpoint Capital Advisors LP makes up 77.78% of all shares held by Fennec Pharmaceuticals insiders.
Institutional investors held 46.58% of Fennec Pharmaceuticals stock at the end of Q2 2026, while the latest Form 4 filings of its insiders account for about 10.07%; other investors, including the public, hold roughly 43.35%.
A total of 77 Form 4 filings with transactions in Fennec Pharmaceuticals stock were made over the past 12 months, by 11 insiders.
Insider figures for FENC include Form 4 filings through October 13, 2026.

Form 4 Holdings

Insiders Holding FENC

Insiders 9

Shares held 3.57Mn

Of outstanding 10.19%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Capital Advisors Lp Southpoint	TenPercentOwner	0	2,744,741	2,744,741	76.9%	29 Dec, 2025
2	Robert Andrade	Chief Financial Officer	246,855	0	246,855	6.9%	13 Oct, 2026
3	Khalid Islam	Director	213,825	0	213,825	6.0%	16 Nov, 2023
4	Rosty Raykov	Chief Executive Officer	124,411	0	124,411	3.5%	01 Sep, 2026
5	Jeffrey S. Hackman	Chief Executive Officer	69,685	0	69,685	2.0%	13 Oct, 2026
6	Chris A Rallis	Director	63,077	0	63,077	1.8%	12 May, 2026
7	Terry L Evans	Chief Commercial Officer	44,692	0	44,692	1.3%	13 Oct, 2026
8	Pierre Sargis Sayad	Chief Medical Officer	34,212	0	34,212	1.0%	13 Oct, 2026
9	Christiana Marie Cioffi	Chief Strategy Officer	28,746	0	28,746	0.8%	13 Oct, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

450 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
12 Oct, 2026	Christiana Marie Cioffi	Chief Strategy Officer	Acquired A	3,946	$5.53	$21.82K	28,746	Direct
12 Oct, 2026	Robert Andrade	Chief Financial Officer	Acquired A	3,846	$5.53	$21.27K	246,855	Direct
12 Oct, 2026	Jeffrey S. Hackman	Chief Executive Officer	Acquired A	2,224	$5.53	$12.30K	69,685	Direct
12 Oct, 2026	Terry L Evans	Chief Commercial Officer	Acquired A	2,326	$5.53	$12.86K	24,013	Direct
12 Oct, 2026	Pierre Sargis Sayad	Chief Medical Officer	Acquired A	3,846	$5.53	$21.27K	13,533	Direct
30 Sep, 2026	Christiana Marie Cioffi	Chief Strategy Officer	Acquired A	156	$0.00	$0	24,800	Direct
30 Sep, 2026	Robert Andrade	Chief Financial Officer	Acquired A	1,703	$0.00	$0	243,009	Direct
30 Sep, 2026	Jeffrey S. Hackman	Chief Executive Officer	Acquired A	1,159	$0.00	$0	67,461	Direct
30 Sep, 2026	Pierre Sargis Sayad	Chief Medical Officer	Acquired A	168	$0.00	$0	9,687	Direct
30 Sep, 2026	Terry L Evans	Chief Commercial Officer	Acquired A	168	$0.00	$0	21,687	Direct
15 Sep, 2026	Marco Maria Brughera	Director	Acquired M	15,545	$2.11	$32.80K	15,545	Direct
15 Sep, 2026	Marco Maria Brughera	Director	Disposed S	15,545	$10.29	$159.96K	0	Direct
15 Sep, 2026	Marco Maria Brughera	Director	Disposed M	15,545	$0.00	$0	220,000	Direct
31 Aug, 2026	Rosty Raykov	Other	Acquired A	2,778	$0.00	$0	134,411	Direct
01 Sep, 2026	Rosty Raykov	Other	Disposed S	10,000	$12.11	$121.10K	124,411	Direct
31 Aug, 2026	Pierre Sargis Sayad	Chief Medical Officer	Acquired A	168	$0.00	$0	21,519	Direct
31 Aug, 2026	Terry L Evans	Chief Commercial Officer	Acquired A	168	$0.00	$0	21,519	Direct
31 Aug, 2026	Robert Andrade	Chief Financial Officer	Acquired A	1,703	$0.00	$0	241,306	Direct
31 Aug, 2026	Jeffrey S. Hackman	Chief Executive Officer	Acquired A	1,159	$0.00	$0	66,302	Direct
31 Aug, 2026	Christiana Marie Cioffi	Chief Strategy Officer	Acquired A	156	$0.00	$0	24,644	Direct

Showing 1 to 20 of 450 transactions